MRVL and MBCOF Related Headlines
Go Back- Marvel Biosciences reports MB-204 preclinical results in Fragile X model
- Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
- New Autism Research to be Presented at European Purine Scientific Meeting
- Marvel Biosciences receives Australian patent allowance for MB-204
- Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
- Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
- Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
- Marvel Biosciences secures funding for autism drug trial from 5 Horizons
- Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
- Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
- Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
MRVL and MBCOF Related Press Releases
Go Back- Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
- New Autism Research to be Presented at European Purine Scientific Meeting
- Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
- Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
- Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
- Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
- Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
- Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
